Skip to main content
SpringerLink
Log in

Immunmodulierende Substanzen und Zytostatika in der pädiatrischen Rheumatologie

  • Chapter
  • First Online:
Pädiatrische Rheumatologie

Part of the book series: Springer Reference Medizin ((SRM))

  • 1382 Accesses

Zusammenfassung

Immunmodulierende Substanzen und Zytostatika spielen als „disease modifying drugs“ eine herausgehobene Rolle in der Rheumatologie. Die evidenzbasierte Medizin hat hierbei die Entwicklung von Gold und Penicillamin, die therapeutisch heute keine Rolle mehr spielen, hin zu neueren Substanzen getrieben. Viele dieser Substanzen haben sich in kontrollierten Studien im Kindesalter als effektiv erwiesen. In diesem Kapitel werden Wirkmechanismen, Pharmakokinetik, unerwünschte Wirkungen und der praktische Einsatz der folgenden immunmodulierenden Substanzen und Zytostatika im Einzelnen dargestellt: Sulfasalazin, Antimalariamittel, Methotrexat, Leflunomid, Azathioprin, Cyclophosphamid, Ciclosporin, Mycophenolatmofetil.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 229.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Akhavan PS, Su J, Lou W, Gladman DD, Urowitz MB, Fortin PR (2013) The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. J Rheumatol 40(6):831–841

    Article  CAS  PubMed  Google Scholar 

  • Alcântara AC, Leite CA, Leite AC, Sidrim JJ, Silva FS Jr, Rocha FA (2014) A longterm prospective real-life experience with leflunomide in juvenile idiopathic arthritis. J Rheumatol 41(2):338–344

    Article  PubMed  Google Scholar 

  • Appel GB, Contreras G, Dooley MA et al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20:1103–1112

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Aragon E, Chan YH, Ng KH et al (2010) Good outcomes with mycophenolate-cycclosporine-based induction protocol in children with severe proliferative lupus nephritis. Lupus 9:965–973

    Article  Google Scholar 

  • Attanasi M, Lucantoni M, Rapino D, Petrosino MI, Marsili M, Gasparroni G et al (2019) Lung function in children with juvenile idiopathic arthritis: a cross-sectional analysis. Pediatr Pulmonol 54(8):1242–1249

    PubMed  Google Scholar 

  • Austin HA, Klippel JH, Balow JE et al (1986) Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614–619

    Article  PubMed  Google Scholar 

  • Austin HA, Illei GG, Braun MJ, Balow JE (2009) Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. JASN 20:901–911

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ayaz NA, Karadağ ŞG, Çakmak F, Çakan M, Tanatar A, Sönmez HE (2019) Leflunomide treatment in juvenile idiopathic arthritis. Rheumatol Int 39(9):1615–1619

    Article  CAS  PubMed  Google Scholar 

  • Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, Dewitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Martini A, Rabinovich CE, Ruperto N (2011) 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 63:465–482

    Article  Google Scholar 

  • Bichler J, Benseler SM, Krumrey-Langkammerer M, Haas JP, Hügle B (2015) Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis. Scand J Rheumatol 44(4):280–283

    Article  CAS  PubMed  Google Scholar 

  • Brewer EJ, Giannini EH, Kuzmina N, Alekseev L (1986) Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind placebo-controlled trial. N Engl J Med 314:1269–1276

    Article  CAS  PubMed  Google Scholar 

  • Bronsky J, de Ridder L, Ruemmele FM, Griffiths A, Buderus S, Hradsky O, Hauer AC (2019) Diagnostic and therapeutic approach in paediatric inflammatory bowel diseases: results from a clinical practice survey. J Pediatr Gastroenterol Nutr 68(5):676–683

    Article  PubMed  Google Scholar 

  • Burgos-Vargas R et al (2002) A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis 61:941–942

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chan ES, Cronstein BN (2010) Methotrexate–how does it really work? Nat Rev Rheumatol 6:175–178

    Article  CAS  PubMed  Google Scholar 

  • Chande N, Patton PH, Tsoulis DJ, Thomas BS, MacDonald JK (2015) Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev (10)

    Google Scholar 

  • Chickermane PR, Khubchandani RP (2015) Evaluation of the benefits of sequential addition of leflunomide in patients with polyarticular course juvenile idiopathic arthritis failing standard dose methotrexate. Clin Exp Rheumatol 33(2):287–292

    PubMed  Google Scholar 

  • Contreras G, Pardo V, Leclercq B et al (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350:971–980

    Article  CAS  PubMed  Google Scholar 

  • Costedoat-Chalumeau N, Amoura Z, Huong DL, Lechat P, Piette JC (2005) Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun Rev 4:111–115

    Article  CAS  PubMed  Google Scholar 

  • Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH (2001) Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 60:729–735

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • De Silva M, Hazleman BL (1981) Long-term azathioprine in rheumatoid arthritis: a double-blind study. Ann Rheum Dis 40(6):560–563

    Article  PubMed  PubMed Central  Google Scholar 

  • Decarriere G, Barnetche T, Combe B, Gaujoux-Viala C, Lukas C, Morel J, Daien C (2020) The most appropriate conventional DMARD to combine with different advanced therapies in rheumatoid arthritis: a systematic literature review with meta-analysis. Arthritis Care Res

    Google Scholar 

  • Deng J, Xie H, Zhu L, Luo L, Xie H (2019) Maintenance therapy for lupus nephritis with mycophenolate mofetil or azathioprine. A meta-analysis. Clin Nephrol 91(3):172–179

    Article  CAS  PubMed  Google Scholar 

  • Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D et al (2011) Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365(20):1886–1895

    Article  CAS  PubMed  Google Scholar 

  • Dueckers G, Guellac N, Arbogast M, Dannecker G, Foeldvari I, Frosch M, Ganser G, Heiligenhaus A, Horneff G, Illhardt A, Kopp I, Krauspe R, Markus B, Michels H, Schneider M, Singendonk W, Sitter H, Spamer M, Wagner N, Niehues T (2012) Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol 142(2):176–193

    Article  CAS  PubMed  Google Scholar 

  • Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, Boletis J, Frangou E, Houssiau FA, Hollis J, Karras A, Marchiori F, Marks SD, Moroni G, Mosca M, Parodis I, Praga M, Schneider M, Smolen JS, Tesar V, Trachana M, Vollenhoven RF v, Voskuyl AE, Teng YKO, Leew B v, Bertsias G, Jayne D, Boumpas DT (2020) Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 79:713–723

    Article  CAS  PubMed  Google Scholar 

  • Fiehn C, Holle J, Iking-Konert C, Leipe J, Weseloh C, Frerix M, Alten R, Behrens F, Baerwald C, Braun J, Burkhardt H, Burmester G, Detert J, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Krause A, Kuipers J, Lorenz HM, Müller-Ladner U, Nothacker M, Nüsslein H, Rubbert-Roth A, Schneider M, Schulze-Koops H, Seitz S, Sitter H, Specker C, Tony HP, Wassenberg S, Wollenhaupt J, Krüger K (2018) S2e-Leitlinie: Therapie der rheumatoiden Arthritis mit krankheitsmodifizierenden Medikamenten [S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs]. Z Rheumatol 77(Suppl 2):35–53

    Article  CAS  PubMed  Google Scholar 

  • Fischer-Betz R, Schneider M (2009) Antimalariamittel. Therapieoption für jeden Lupus-Patienten?! Z Rheumatol 68:584–590

    Article  CAS  PubMed  Google Scholar 

  • Foeldvari I, Wierk A (2010) Effectiveness of leflunomide in patients with juvenile idiopathic arthritis in clinical practice. J Rheumatol 37(8):1763–1767

    Article  CAS  PubMed  Google Scholar 

  • Fu LW, Yang LY, Chen WP, Lin CY (1998) Clinical efficacy of cyclosporin a neoral in the treatment of paediatric lupus nephritis with heavy proteinuria. Br J Rheumatol 37:217–221

    Article  CAS  PubMed  Google Scholar 

  • Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A (1997) Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 40:1202–1209

    Article  CAS  PubMed  Google Scholar 

  • Ginzler EM, Dooley MA, Aranow C et al (2005) Myclophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. NEJM 353:2219–2228

    Article  CAS  PubMed  Google Scholar 

  • Gjuladin-Hellon T, Iheozor-Ejiofor Z, Gordon M, Akobeng AK (2019) Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease. Cochrane Database Syst Rev 8(8):CD010233

    PubMed  Google Scholar 

  • Golicki D, Niewada M, Lis J, Pol K, Hermanowski T, Tlustochowicz M (2012) Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomised trials. Pol Arch Med Wewn [Epub ahead of print]

    Google Scholar 

  • Grabar PB, Rozman B, Tomsic M, Suput D, Logar D, Dolzan V (2008) Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur J Clin Pharmacol 64:871–876

    Article  CAS  Google Scholar 

  • Grabar PB, Rozman B, Logar D, Praprotnik S, Dolzan V (2009) Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis. Ann Rheum Dis 68:1367–1368

    Article  CAS  PubMed  Google Scholar 

  • Groot N, de Graeff N, Marks SD et al (2017) European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis 76:1965–1973

    Article  CAS  PubMed  Google Scholar 

  • Hamdy H, McKendry RJ, Mierins E, Liver JA (1987) Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A twenty-four-week controlled clinical trial. Arthritis Rheum 30(4):361–368

    Article  CAS  PubMed  Google Scholar 

  • Hazlewood GS, Barnabe C, Tomlinson G, Marshall D, Devoe DJ, Bombardier C (2016) Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: a network meta-analysis. Cochrane Database Syst Rev (8)

    Google Scholar 

  • Hoffmann C (2020) covidreference. https://covidreference.com/treatment_de. Zugegriffen am 20.01.2020

  • Horne A, Delcoigne B, Palmblad K, Askling J (2019) Juvenile idiopathic arthritis and risk of cancer before and after the introduction of biological therapies. RMD Open 5(2):e001055

    Article  PubMed  PubMed Central  Google Scholar 

  • Horneff G, Klein A, Oommen PT, Hospach A, Foeldvari I, Feddersen I, Minden K (2016) Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER Registry. Clin Exp Rheumatol 34(6):1113–1120

    PubMed  Google Scholar 

  • Huang SZ, Liu ZC, Liao WX, Wei JX, Huang XW, Yang C, Xia YH, Li L, Ye C, Dai SX (2019) Risk of skin cancers in thiopurines-treated and thiopurines-untreated patients with inflammatory bowel disease: a systematic review and meta-analysis. J Gastroenterol Hepatol 34(3):507–516

    Article  PubMed  Google Scholar 

  • Hugle B (2019) MTX intolerance in children and adolescents with juvenile idiopathic arthritis. Z Rheumatol 78(7):620–626

    Article  CAS  PubMed  Google Scholar 

  • Husby G (1978) Antimalarials, gold and penicillamine. In: Munthe E (Hrsg) The care of rheumatic children. EULAR Publishers, Basle, S 55–59

    Google Scholar 

  • Imundo LF, Jacobs JC (1996) Sulfasalazine therapy for juvenile rheumatoid arthritis. J Rheumatol 23:360–366

    CAS  PubMed  Google Scholar 

  • Jaeger A, Sauder P, Kopferschmitt J, Flesch F (1987) Clinical features and management of poisoning due to antimalarial drugs. Med Toxicol Adverse Drug Exp 2:242–273

    CAS  PubMed  Google Scholar 

  • Jeurissen ME, Boerbooms AM, van de Putte LB, Doesburg WH, Mulder J, Rasker JJ et al (1991) Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight-week randomized, double-blind trial. Arthritis Rheum 34(8):961–972

    Article  CAS  PubMed  Google Scholar 

  • Jiyad Z, Olsen CM, Burke MT, Isbel NM, Green AC (2016) Azathioprine and risk of skin cancer in organ transplant recipients: systematic review and meta-analysis. Am J Transplant 16(12):3490–3503

    Article  CAS  PubMed  Google Scholar 

  • Jones RB, Heimstra TF, Ballarin J et al (2019) Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomized, non-inferiority trial. Ann Rheum Dis 78:399–405

    Article  CAS  PubMed  Google Scholar 

  • Kazyra I, Pilkington C, Marks SD, Tullus K (2010) Mycophenolate mofetil treatment in children and adolescents with lupus. Arch Dis Child 95:1059–1061

    Article  PubMed  Google Scholar 

  • Klein A, Kaul I, Foeldvari I, Ganser G, Urban A, Horneff G (2012) Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry. Arthritis Care Res 64(9):1349–1356

    Article  CAS  Google Scholar 

  • Kotlyar DS, Lewis JD, Beaugerie L, Tierney A, Brensinger CM, Gisbert JP, Loftus EV Jr, Peyrin-Biroulet L, Blonski WC, Van Domselaar M, Chaparro M, Sandilya S, Bewtra M, Beigel F, Biancone L, Lichtenstein GR (2015) Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol 13(5):847–858

    Article  CAS  PubMed  Google Scholar 

  • Kruize AA, Hene RJ, Kallenberg CG et al (1993) Hydroxychloroquine treatment for primary Sjogren’s syndrome: a two year double blind crossover trial. Ann Rheum Dis 52(5):360–364

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kvien TK, Hoyeraal HM, Sandstad B (1985) Slow acting antirheumatic drugs in patients with juvenile rheumatoid arthritis – evaluated in a randomized, parallel 50-week clinical trial. J Rheumatol 12(3):533–539

    CAS  PubMed  Google Scholar 

  • Kvien TK, Hoyeraal HM, Sandstad B (1986) Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study. J Rheumatol 13:118–123

    CAS  PubMed  Google Scholar 

  • Lee YH, Song GG (2017) Comparative efficacy and safety of tacrolimus, mycophenolate mofetil, azathioprine, and cyclophosphamide as maintenance therapy for lupus nephritis: a Bayesian network meta-analysis of andomized controlled trials. Z Rheumatol 76(10):904–912

    Article  CAS  PubMed  Google Scholar 

  • Lehman TJA, Edelheit BS, Onel KB (2004) Combined intravenous methotrexate and cyclophosphamide for refractory childhood lupus nephritis. Ann Rheum Dis 63:321–323

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, Dray-Spira R (2017) Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA 318(17):1679–1686

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Li EK, Tam LS, Tomlinson B (2004) Leflunomide in the treatment of rheumatoid arthritis. Clin Ther 26:447–459

    Article  CAS  PubMed  Google Scholar 

  • Lin YT, Yang YH, Tsai MJ, Chiang BL (2000) Long-term effects of azathioprine therapy for juvenile rheumatoid arthritis. J Formos Med Assoc 99(4):330–335

    CAS  PubMed  Google Scholar 

  • Masuda K, Nakajima A, Urayama K et al (1989) Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet’s disease. Lancet 1:1093–1096

    Article  CAS  PubMed  Google Scholar 

  • Miettunen PM, Pistorio A, Palmisani E, Ravelli A, Silverman E, Oliveira S, Alessio M, Cuttica R, Mihaylova D, Espada G, Pasic S, Insalaco A, Ozen S, Porras O, Sztajnbok F, Lazarevic D, Martini A, Ruperto N, Paediatric Rheumatology International Trials Organisation (PRINTO) (2013) Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicentre PRINTO study. Ann Rheum Dis 72(9):1503–1509

    Article  CAS  PubMed  Google Scholar 

  • Mina R, von Scheyven E, Ardoin SP et al (2012) Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res 64:375–383

    Article  Google Scholar 

  • Moroni G, Raffiotta F, Trezzi B et al (2014) Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. Rheumatology 53:1570–1577

    Article  CAS  PubMed  Google Scholar 

  • Neurath M (2010) Thiopurines in IBD: what is their mechanism of action? Gastroenterol Hepatol (N Y) 6:435–436

    Google Scholar 

  • Olson NY, Lindsley CB (1989) Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol 16(12):1545–1547

    CAS  PubMed  Google Scholar 

  • Oommen PT (2020) Handlungsempfehlung nach der S2k-Leitlinie Therapie der juvenilen idiopathischen Arthritis. Monatsschr Kinderheilkd

    Google Scholar 

  • Poppe D, Tiede I, Fritz G, Becker C, Bartsch B, Wirtz S, Strand D, Tanaka S, Galle PR, Bustelo XR, Neurath MF (2006) Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol 176:640–651

    Article  CAS  PubMed  Google Scholar 

  • Prakash A, Jarvis B (1999) Leflunomide: a review of its use in active rheumatoid arthritis. Drugs 58:1137–1164

    Article  CAS  PubMed  Google Scholar 

  • Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S et al (2017) Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med 376(17):1637–1646

    Article  CAS  PubMed  Google Scholar 

  • Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Klein TE (2011) Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 89:387–391

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 69:20–28

    Article  CAS  PubMed  Google Scholar 

  • Ruperto N, Murray KJ, Gerloni V et al (2004) A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 50:2191–2201

    Article  CAS  PubMed  Google Scholar 

  • Schrezenmeier E, Dorner T (2020) Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 16(3):155–166

    Article  CAS  PubMed  Google Scholar 

  • Silverman E, Spiegel L, Hawkins D et al (2005) Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 52:554–562

    Article  CAS  PubMed  Google Scholar 

  • Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, Heijde D v d (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76(6):960–977

    Article  PubMed  Google Scholar 

  • Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis

    Google Scholar 

  • Stoeber E (1976) Corticosteroid treatment of juvenile chronic polyarthritis over 22 years. Eur J Pediatr 121:141–147

    Article  CAS  PubMed  Google Scholar 

  • Suarez-Almazor ME, Spooner C, Belseck E (2000a) Azathioprine for treating rheumatoid arthritis. Cochrane Database Syst Rev (4):CD001461. https://doi.org/10.1002/14651858.CD001461. PMID: 11034720

  • Suarez-Almazor ME, Belseck E, Shea B, Homik J, Wells G, Tugwell P (2000b) Antimalarials for treating rheumatoid arthritis. Cochrane Database Syst Rev 4:CD000959

    Google Scholar 

  • Thai A, Prindiville T (2010) Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J Crohns Colitis 4(5):511–522

    Article  PubMed  Google Scholar 

  • Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, Lehr HA, Wirtz S, Becker C, Atreya R, Mudter J, Hildner K, Bartsch B, Holtmann M, Blumberg R, Walczak H, Iven H, Galle PR, Ahmadian MR, Neurath MF (2003) CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 111:1133–1145

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Timmer A, Patton PH, Chande N, McDonald JW, MacDonald JK (2016) Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev (5)

    Google Scholar 

  • Tönnesmann E et al (2012) Cardiomyopathy caused by longterm treatment with chloroquine: a rare disease, or a rare diagnosis? J Rheumatol 39(5):1099–1103

    Article  CAS  PubMed  Google Scholar 

  • Rossum MA Van, Fiselier TJ, Franssen MJ et al. (1998) Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, doubleblind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 41:808–816

    Google Scholar 

  • Rossum MA Van , Soesbergen RM van, Boers M et al. (2007) Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefit of early sulfasalazine treatment. Ann Rheum Dis 66:1518–1524

    Google Scholar 

  • Wallace DJ (2020) Antimalarial drugs in the treatment of rheumatic disease uptodate.com. https://uptodate.helios-zentralbibliothek.de/contents/antimalarial-drugs-in-the-treatment-of-rheumatidisease?search=antimalarial&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2. Zugegriffen am 20.01.2020

  • Woo P, Southwood TR, Prieur AM et al (2000) Randomized, placebocontrolled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 43:1849–1857

    Article  CAS  PubMed  Google Scholar 

  • Yusuf IH, Foot B, Galloway J, Ardern-Jones MR, Watson SL, Yelf C et al (2018) The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary. Eye (Lond) 32(7):1168–1173

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Helios Kliniken Krefeld, Zentrum für Kinder- und Jugendmedizin, Krefeld, Deutschland

    Tim Niehues

  2. Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Aachen, Aachen, Deutschland

    Norbert Wagner

  3. Klinik und Poliklinik für Kinder- und Jugendmedizin, Pädiatrische Immunologie, Technischen Universität Dresden, Universitätsklinikum Carl Gustav Carus, Dresden, Deutschland

    Catharina Schütz

  4. Klinik für Kinder- und Jugendmedizin I, Universitätsklinikum Schleswig Holstein Kiel, Kiel, Deutschland

    Philipp von Bismarck

Authors
  1. Tim Niehues
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Norbert Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Catharina Schütz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Philipp von Bismarck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tim Niehues .

Editor information

Editors and Affiliations

  1. Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Aachen, Aachen, Deutschland

    Norbert Wagner

  2. Sektion Rheumatologie der Klinik für Pädiatrie m.S. Pneumologie, Immunologie und Intensivmedizin mit Bereich Rheumatologie, im Sozialpädiatrischen ZentrumCharité - Universitätsmedizin Berlin, Berlin, Deutschland

    Günther Dannecker

  3. Sektion Rheumatologie der Klinik für Pädiatrie m.S. Pneumologie, Immunologie und Intensivmedizin mit Bereich Rheumatologie, im Sozialpädiatrischen ZentrumCharité - Universitätsmedizin Berlin, Berlin, Deutschland

    Tilmann Kallinich

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Niehues, T., Wagner, N., Schütz, C., von Bismarck, P. (2022). Immunmodulierende Substanzen und Zytostatika in der pädiatrischen Rheumatologie. In: Wagner, N., Dannecker, G., Kallinich, T. (eds) Pädiatrische Rheumatologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-60410-6_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-60410-6_16

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-60409-0

  • Online ISBN: 978-3-662-60410-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation